A comprehensive map of missense trafficking variants in rhodopsin and their response to pharmacologic correction
Kannan Vrindavan ManianiD, Connor LudwigiD, Yan ZhaoiD, Nathan S. AbelliD, Robert Warneford-ThomsoniD, Henry ChaniD, Zachary O. Casey, Xiaoping YangiD, David E. RootiD, Matthew L. AlbertiD, Jason ComanderiD
Abstract
Rhodopsin (RHO) missense variants are a leading cause of autosomal dominant retinitis pigmentosa (adRP), a progressive retinal degeneration with no currently approved therapies. Interpreting the pathogenicity of the growing number of identified RHO variants is a major clinical challenge, and understanding their disease mechanisms is essential for developing effective therapies. Here, we present a high-resolution map of RHO missense variant trafficking using two complementary deep mutational scanning (DMS) approaches based on a surface abundance immunoassay and a membrane proximity assay. We generated a comprehensive dataset encompassing all 6,612 possible single-residue missense variants, revealing a strong correlation between the two methods. Over 700 variants were identified with pathogenic trafficking scores, significantly expanding the number of RHO variants with functional evidence supporting pathogenicity. We demonstrate a high concordance between the trafficking scores and ClinVar pathogenicity classifications, highlighting this approachs utility in resolving variants of uncertain significance (VUS). The data also identified structurally clustered trafficking-deficient variants, predominantly within the N-terminal region and second extracellular loop, in and above the extracellular/intradiscal beta-plug region. Furthermore, we evaluated the efficacy of the non-retinoid pharmacological chaperone YC-001, observing significant rescue of trafficking defects in a majority of mistrafficking variants. This comprehensive functional map of RHO missense variants provides a valuable resource for pathogenicity assessment, genotype-phenotype correlations, and the development of targeted therapeutic strategies for RHO-adRP, paving the way for improved diagnosis and treatment for patients.
02 /Specification & Classification
Click any tag to browse matching papers- Citations
- 3
- FWCI
- 2.04
- Field percentile
- top 22%
- Organism
- Assay
- Research Focus
- Approach
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- A survey of opsin localization, glycosylation, and light/chromophore influence on degeneration in 26 rhodopsin-associated retinitis pigmentosa models
Aaron D. Loewen, Beatrice M. Tam, … Orson L. Moritz·bioRxiv·Jul 23, 2025
- Characterizing variants of unknown significance inrhodopsin: a functional genomics approach
Aliete Wan, Emily Place, … Jason Comander·Human MutationPeer-reviewed·Apr 12, 2019
- Molecular Basis for Variations in the Sensitivity of Pathogenic Rhodopsin Variants to 9-cis-Retinal
F. J. Roushar, A. G. McKee, … J. P. Schlebach·bioRxiv·Mar 1, 2022
- A mutation-agnostic and allele-specific ASO strategy demonstrates potent functional rescue and retinal preservation in RHO-linked retinitis pigmentosa
Salome Spaag, Wen-Hsuan Wu, … Pietro De Angeli·bioRxiv·Sep 1, 2026
- Ocular delivery of different VCP inhibitory formulations prevents retinal degeneration in rhodopsin 255 isoleucine deletion mice
Bowen Cao, Regine L. Mühlfriedel, … Blanca Arango‐González·bioRxiv·Jun 25, 2025
- Autosomal dominant Retinitis Pigmentosa caused by the rhodopsin isoleucine 255 deletion features rapid neuroretinal degeneration, decreased synaptic connectivity, and neuroinflammation.
Bowen Cao, Yu Zhu, … Marius Ueffing·bioRxiv·Aug 29, 2024